Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 3/2015

01-03-2015 | Letter to the Editor

Quantitative Methods for Prediction of the Effect of Cytochrome P450 Gene Polymorphisms on Substrate Drug Exposure

Authors: Sylvain Goutelle, Michel Tod

Published in: Clinical Pharmacokinetics | Issue 3/2015

Login to get access

Excerpt

We read with interest the article by Chang and colleagues who studied the influence of cytochrome P450 2C19 (CYP2C19) genetic polymorphism on citalopram and escitalopram exposure by using meta-analysis [1]. The authors state that this is the first study which provides precise estimates of the influence of CYP2C19 genotypes on (es)citalopram drug exposure, especially for heterozygous genotypes with the CYP2C19*17 gain-of-function allele. …
Literature
1.
Chang M, Tybring G, Dahl ML, Lindh JD. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis. Clin Pharmacokinet. 2014;53(9):801–11.CrossRefPubMed
2.
Goutelle S, Bourguignon L, Bleyzac N, Berry J, Clavel-Grabit F, Tod M. In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates. AAPS J. 2013;15(2):415–26.CrossRefPubMedCentralPubMed
3.
Tod M, Goutelle S, Gagnieu MC. Genotype-based quantitative prediction of drug exposure for drugs metabolized by CYP2D6. Clin Pharmacol Ther. 2011;90(4):582–7.CrossRefPubMed
4.
Castellan AC, Tod M, Gueyffier F, Audars M, Cambriels F, Kassai B, et al. Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure. Clin Pharmacokinet. 2013;52(3):199–209.CrossRefPubMed
5.
Weiss J, Ten Hoevel MM, Burhenne J, Walter-Sack I, Hoffmann MM, Rengelshausen J, et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol. 2009;49(2):196–204.CrossRefPubMed
6.
Tod M, Nkoud-Mongo C, Gueyffier F. Impact of genetic polymorphism on drug–drug interactions mediated by cytochromes: a general approach. AAPS J. 2013;15(4):1242–52.CrossRefPubMedCentralPubMed
Metadata
Title
Quantitative Methods for Prediction of the Effect of Cytochrome P450 Gene Polymorphisms on Substrate Drug Exposure
Authors
Sylvain Goutelle
Michel Tod
Publication date
01-03-2015
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 3/2015
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-014-0217-3

Other articles of this Issue 3/2015

Clinical Pharmacokinetics 3/2015 Go to the issue

Review Article

Drug Transporters in the Central Nervous System

Letter to the Editor

Quantitative Methods for Prediction of the Effect of Cytochrome P450 Gene Polymorphisms on Substrate Drug Exposure: Authors’ Reply

Original Research Article

Efficacy of Tolvaptan Added to Furosemide in Heart Failure Patients with Advanced Kidney Dysfunction: A Pharmacokinetic and Pharmacodynamic Study

Commentary

Nitrite: On the Journey from Toxin to Therapy

Original Research Article

A Population Pharmacokinetic Model of Valproic Acid in Pediatric Patients with Epilepsy: A Non-Linear Pharmacokinetic Model Based on Protein-Binding Saturation

Original Research Article

Application of Modeling and Simulation to a Long-Term Clinical Trial: A Direct Comparison of Simulated Data and Data Actually Observed in Japanese Osteoporosis Patients Following 3-Year Ibandronate Treatment